Last reviewed · How we verify
iCaspase9-transduced T cells
At a glance
| Generic name | iCaspase9-transduced T cells |
|---|---|
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Administration of Donor T Cells With the Caspase-9 Suicide Gene (PHASE1)
- 3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- iCaspase9-transduced T cells CI brief — competitive landscape report
- iCaspase9-transduced T cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI